|
|
| Crohn's Disease | Visit Website |
1-877-240-7528 |
sales@crohns.net |
Why Shop Crohns.net? |
Quick Product Links
|
|
Crohn's Disease- Pathophysiology and Conventional and Alternative Treatment OptionsTable 1: Subcategories of Crohn's Disease Table 2: Signs and Symptoms of Crohn's Disease and Ulcerative Colitis Etiopathogenesis:
Stress in the Etiology of Crohn's Disease Other Abnormalities Contributing to the Etiopathogenesis of Crohn's Disease Conventional Treatment of Crohn's Disease Table 5: Conventional Medications and their Mechanisms in Crohn's Disease Nutrient Deficiences in Crohn's Disease Table 6: nutrient Deficiencies Associated with Crohn's Disease Dietary Interventions in Crohn's Disease Table 7: Diet Therapies Compared to Steroid Medications in Crohn's Disease Probiotics in the Treatment of Crohn's Disease Fatty Acids for the Treatment of Crohn's Disease Table 8: A Summary of Omega-3 Fatty Acid Studies in Crohn's Disease Remicade Increasing Risk of Cancer Botanicals in the Treatment of Crohn's Disease |
DHEADehydroepiandrosterone (DHEA) is low in patients with Crohn's Disease. In a study of 115 Crohn's Disease patients compared to 66 healthy controls and 64 UC patients, both Crohn's Disease and Ulcerative Colitis patients had low serum DHEA-sulfate (DHEAS) levels compared to controls. In Crohn's Disease patients, but not Ulcerative Colitis patients, low DHEAS levels were correlated with high ESR, while high cortisol was associated with high ESR and CRP.258 Another study found a shift in the ratio of cortisol:DHEA in Crohn's Disease patients with active disease, with higher cortisol and lower DHEA levels. 259
Because Dehydroepiandrosterone can be deficient in
patients with IBD and has also been shown to
inhibit pro-inflammatory cytokines, a phase 2 pilot
trial was conducted to evaluate its effect in IBD
patients. Twenty patients (seven with Crohn's Disease; 13 with
Ulcerative Colitis), ages 18-45, were given 200 mg Dehydroepiandrosterone orally
once daily for 56 days. All patients were
experiencing active disease, defined as CDAI >
150, refractory to other medications. All
medications remained the same for two weeks
prior to and during the study. One patient with Crohn's Disease
(and four with Ulcerative Colitis) dropped out because of disease
exacerbation or noncompliance. In the Crohn's Disease group,
six of seven responded to treatment with a decrease
in CDAI of 70 points or more. In all six responders,
the CDAI dropped below 150, putting them into
remission. The one patient who did not respond
dropped out during the first week. Number of
liquid stools, bloody diarrhea, abdominal pain, and
CRP all decreased. One Crohn's Diseas patient relapsed on
day 56. Patients were followed for eight weeks
after the end of the study and no further Crohn's Disease
relapses were reported.260
|
|
|
Call 1-877-240-7528 • Mon-Fri 9am-5pm PST P.O. Box 927747 ~ San Diego ~ California ~ 92192 ~ USA Home | About Us | Quick Product Links | Search | Help |
||